MYGN Myriad Genetics Inc

Price (delayed)

$31.74

Market cap

$2.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.29

Enterprise value

$2.56B

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
The EPS has soared by 52% YoY and by 35% from the previous quarter
The company's net income has surged by 51% YoY and by 34% QoQ
The quick ratio has dropped by 51% year-on-year and by 48% since the previous quarter

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
78.06M
Market cap
$2.48B
Enterprise value
$2.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.71
Price to sales (P/S)
3.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.86
Earnings
Revenue
$662.3M
EBIT
-$136.7M
EBITDA
-$52.4M
Free cash flow
$6.7M
Per share
EPS
-$1.29
Free cash flow per share
$0.09
Book value per share
$11.71
Revenue per share
$8.58
TBVPS
$8.98
Balance sheet
Total assets
$1.36B
Total liabilities
$457.9M
Debt
$200.7M
Equity
$902.5M
Working capital
$267.9M
Liquidity
Debt to equity
0.22
Current ratio
1.99
Quick ratio
0.96
Net debt/EBITDA
-1.57
Margins
EBITDA margin
-7.9%
Gross margin
70.5%
Net margin
-14.7%
Operating margin
-22.7%
Efficiency
Return on assets
-7%
Return on equity
-10.9%
Return on invested capital
-27.7%
Return on capital employed
-12.5%
Return on sales
-20.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
-1.61%
1 week
2.78%
1 month
-3%
1 year
154.74%
YTD
60.47%
QTD
-1.7%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$662.3M
Gross profit
$466.9M
Operating income
-$150.5M
Net income
-$97.3M
Gross margin
70.5%
Net margin
-14.7%
The net margin has soared by 53% YoY and by 44% from the previous quarter
The company's net income has surged by 51% YoY and by 34% QoQ
The company's operating margin rose by 38% YoY and by 35% QoQ
The operating income rose by 36% YoY and by 24% QoQ

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
2.71
P/S
3.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.86
The EPS has soared by 52% YoY and by 35% from the previous quarter
MYGN's price to book (P/B) is 36% higher than its 5-year quarterly average of 2.0 and 36% higher than its last 4 quarters average of 2.0
The company's equity rose by 3.1% QoQ
The P/S is 37% higher than the 5-year quarterly average of 2.7 and 23% higher than the last 4 quarters average of 3.0
Myriad Genetics's revenue has increased by 17% QoQ and by 3.7% YoY

Efficiency

How efficient is Myriad Genetics business performance
Myriad Genetics's return on assets has increased by 47% YoY and by 34% QoQ
MYGN's return on equity is up by 45% year-on-year and by 34% since the previous quarter
The ROS has grown by 39% from the previous quarter and by 38% YoY
The return on invested capital has grown by 30% since the previous quarter and by 27% year-on-year

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 197% more than its total liabilities
The quick ratio has dropped by 51% year-on-year and by 48% since the previous quarter
Myriad Genetics's current ratio has decreased by 12% YoY and by 10% from the previous quarter
The debt is 78% less than the equity
The debt has contracted by 32% YoY and by 8% from the previous quarter
The debt to equity is down by 31% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.